- Home
- ADAG vs PLRX Comparison
ADAG vs PLRX Comparison
Compare ADAG & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAG
- PLRX
- Stock Information
- Founded
- ADAG 2011
- PLRX 2015
- Country
- ADAG China
- PLRX United States
- Employees
- ADAG N/A
- PLRX N/A
- Industry
- ADAG Biotechnology: Pharmaceutical Preparations
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- ADAG Health Care
- PLRX Health Care
- Exchange
- ADAG Nasdaq
- PLRX Nasdaq
- Market Cap
- ADAG 110.8M
- PLRX 93.3M
- IPO Year
- ADAG 2021
- PLRX 2020
- Fundamental
- Price
- ADAG $1.95
- PLRX $1.47
- Analyst Decision
- ADAG Strong Buy
- PLRX Hold
- Analyst Count
- ADAG 3
- PLRX 10
- Target Price
- ADAG $7.67
- PLRX $3.93
- AVG Volume (30 Days)
- ADAG 60.8K
- PLRX 370.4K
- Earning Date
- ADAG 08-12-2025
- PLRX 11-06-2025
- Dividend Yield
- ADAG N/A
- PLRX N/A
- EPS Growth
- ADAG N/A
- PLRX N/A
- EPS
- ADAG N/A
- PLRX N/A
- Revenue
- ADAG $103,204.00
- PLRX N/A
- Revenue This Year
- ADAG $7,411.34
- PLRX N/A
- Revenue Next Year
- ADAG $28.29
- PLRX N/A
- P/E Ratio
- ADAG N/A
- PLRX N/A
- Revenue Growth
- ADAG N/A
- PLRX N/A
- 52 Week Low
- ADAG $1.33
- PLRX $1.10
- 52 Week High
- ADAG $3.16
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- ADAG 44.56
- PLRX 47.05
- Support Level
- ADAG $1.85
- PLRX $1.42
- Resistance Level
- ADAG $2.06
- PLRX $1.55
- Average True Range (ATR)
- ADAG 0.11
- PLRX 0.08
- MACD
- ADAG -0.01
- PLRX -0.00
- Stochastic Oscillator
- ADAG 26.08
- PLRX 48.28
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.